These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 29371019)

  • 21. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
    Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
    Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model.
    Eldin NE; Abu Lila AS; Kawazoe K; Elnahas HM; Mahdy MA; Ishida T
    Eur J Pharm Sci; 2016 Jan; 81():60-6. PubMed ID: 26415830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge.
    Dadashzadeh S; Mirahmadi N; Babaei MH; Vali AM
    J Control Release; 2010 Dec; 148(2):177-86. PubMed ID: 20800629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intra-articular delivery of liposomal celecoxib-hyaluronate combination for the treatment of osteoarthritis in rabbit model.
    Dong J; Jiang D; Wang Z; Wu G; Miao L; Huang L
    Int J Pharm; 2013 Jan; 441(1-2):285-90. PubMed ID: 23194887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin.
    Chow DS; Gong L; Wolfe MD; Giovanella BC
    Ann N Y Acad Sci; 2000; 922():164-74. PubMed ID: 11193891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
    Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
    Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Derma roller® microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect.
    Ahmed KS; Shan X; Mao J; Qiu L; Chen J
    Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1448-1458. PubMed ID: 30889679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
    Shaji J; Menon I
    Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
    Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
    Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carboranyl Analogues of Celecoxib with Potent Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines.
    Buzharevski A; Paskas S; Sárosi MB; Laube M; Lönnecke P; Neumann W; Mijatovic S; Maksimovic-Ivanic D; Pietzsch J; Hey-Hawkins E
    ChemMedChem; 2019 Feb; 14(3):315-321. PubMed ID: 30602073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
    Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
    Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attenuation of celecoxib cardiac toxicity using Poly(δ-decalactone) based nanoemulsion via oral route.
    Maru S; Verma J; Wilen CE; Rosenholm JM; Bansal KK
    Eur J Pharm Sci; 2023 Nov; 190():106585. PubMed ID: 37717666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
    Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
    J Pharm Sci; 2011 Jul; 100(7):2835-48. PubMed ID: 21305545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
    Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
    J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposome formulation of a novel hydrophobic aryl-imidazole compound for anti-cancer therapy.
    Liu J; Lee H; Huesca M; Young A; Allen C
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):306-18. PubMed ID: 16333677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo pharmacokinetics of celecoxib loaded endcapped PCLA-PEG-PCLA thermogels in rats after subcutaneous administration.
    van Midwoud PM; Sandker M; Hennink WE; de Leede LGJ; Chan A; Weinans H
    Eur J Pharm Biopharm; 2018 Oct; 131():170-177. PubMed ID: 30075312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
    Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity of PEGylated nanoliposomes containing crocin in mice bearing C26 colon carcinoma.
    Rastgoo M; Hosseinzadeh H; Alavizadeh H; Abbasi A; Ayati Z; Jaafari MR
    Planta Med; 2013 Apr; 79(6):447-51. PubMed ID: 23539350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.
    Bhatia A; Kumar R; Katare OP
    J Pharm Pharm Sci; 2004 Jul; 7(2):252-9. PubMed ID: 15367383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
    Lo YL; Liu Y; Tsai JC
    Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.